openPR Logo
Press release

Non-Small Cell Lung Cancer Therapeutics Market Latest trends in Healthcare IT Industry

02-14-2017 10:58 PM CET | Health & Medicine

Press release from: Transparency Market Research - Pharmaceutical

Non-Small Cell Lung Cancer Therapeutics Market Latest trends

Transparency Market Research has published a new market report titled, “Non Small Cell Lung Cancer Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023.” According to the report, the global non small cell lung cancer market was valued at US$ 4.9 Bn in 2014 and is anticipated to expand at a CAGR of 12.1% from 2015 to 2023 to reach US$ 15.1 Bn in 2023.

Browse the full Non Small Cell Lung Cancer Therapeutics Market: (By Drug Class: Angiogenesis Inhibitor, EGFR Inhibitor, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, and PD-1/PD-L1 Inhibitor): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 – 2023 report at http://www.transparencymarketresearch.com/non-small-cell-lung-cancer-market.html

The report provides detailed analysis of current and emerging drugs for non small cell lung cancer (NSCLC), segmenting them based on type of drug class. Drugs have been analyzed by segments such as angiogenesis inhibitor, EGFR inhibitor, kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/PD-L1 inhibitor. Angiogenesis inhibitor was the largest segment of the global non-small cell lung cancer market in 2014. High demand for Avastin in major geographies such as Europe and the U.S. is likely to propel the segment during the forecast period. The angiogenesis inhibitor segment was valued at US$ 1,627.1 Mn in 2014 and is likely to account for US$ 2,020.4 Mn by 2023, expanding at a CAGR of 1.8% from 2015 to 2023.

The folate antimetabolites segment is projected to be the second highest segment of the global NSCLC therapeutics market. The EGFR inhibitor and microtubule stabilizer segments held the third and fourth largest shares of the market in terms of revenue in 2014. However, entry of new targeted therapies with more surveillance rate could restrain market growth. PD-1/PD-L1 inhibitor is likely to the fastest growing segment during the forecast period, due to affectivity of the treatment as clinical data showed double survival rate. The non-small cell lung cancer therapeutics market is anticipated to be driven by increase in incidence and diagnosis rate, government initiatives leading to rapid approval of the treatment, and development of targeted therapies.

The report offers a detailed analysis of factors responsible for market growth and outlines a possible growth trajectory for other segments. The report is thus compiled with the primary objective of updating the stakeholders with the market dynamics, which are graphically illustrated.

AstraZeneca plc, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Novartis AG, Eli Lilly and Company, Pfizer, Inc., Genentech, Inc. (a Roche company), and Sun Pharmaceutical Industries Ltd. are the major companies operating in the global non small cell lung cancer therapeutics market. Genentech, a Roche company, was identified as the leading player in the global non-small cell lung cancer therapeutics market in 2014, accounting for a revenue share of more than 36%, followed by Eli Lilly and Company.

The global non-small cell lung cancer therapeutics market has been segmented as follows:

Global Non-Small Cell Lung Cancer Therapeutics Market, by Drug Class, 2013–2023 (US$ Mn)
Overview
Angiogenesis Inhibitor
Avastin (bevacizumab)
Cyramza (Ramucirumab)
Epidermal Growth Factor Receptor Blocker
Tarceva (erlotinib)
Gilotrif (afatinib)
Iressa (gefitinib)
Kinase Inhibitor
Xalkori (crizotinib)
Zykadia (ceritinib)
Microtubule Stabilizer
Abraxane (paclitaxel protein bound)
Docetaxel
Folate Antimetabolites
Alimta (pemetrexed)
PD-1/ PD-L1 Inhibitor
Opdivo (nivolumab)
Keytruda (pembrolizumab)
Pipeline Analysis: Global Non-Small Cell Lung Cancer Therapeutics Market
Overview
Late Stage (Phase III) Forecast for Phase III Drugs Post Expected Launch till 2023 (US$ Mn)
Avelumab – Pfizer, Inc.
MPDL3280A – Roche
MEDI4736 – AstraZeneca
Abemaciclib – Eli Lilly and Company
Others
Early Stage (Phase I and II) (Qualitative Analysis – Tabular representation)
Global Non-Small Cell Lung Cancer Therapeutics Market, by Geography, 2013–2023 (US$ Mn)
Overview
North America
U.S.
Canada
Europe
U.K.
Germany
Rest of Europe
Asia Pacific
Japan
China
Rest of Asia Pacific
Rest of the World

Download Exclusive Brochure of This Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504

About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr.Sudip S
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non-Small Cell Lung Cancer Therapeutics Market Latest trends in Healthcare IT Industry here

News-ID: 437648 • Views: 484

More Releases from Transparency Market Research - Pharmaceutical

Neurovascular Devices Market Business Opportunities and Growth Challenges Report
Global Neurovascular Devices Market: Overview The global population is aging rapidly. According to WHO, the chances of health risks are greater in geriatric people than the young generation. Old age is considered to be one of the biggest risk factors that are responsible for developing various diseases such as cardiovascular and neurological conditions. It is because of these factors, the global neurovascular devices market is experiencing robust growth in the
Pneumococcal Vaccines Market anticipated expand at a CAGR of 3.3% from 2018 to 2 …
Transparency Market Research (TMR) has published a new report titled, “Pneumococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global pneumococcal vaccines market was valued at US$ 7,247.6 Mn in 2017 and is anticipated expand at a CAGR of 3.3% from 2018 to 2026. Increase in patient pool, growth of the pharmaceutical industry, government initiatives to increase vaccination programs, rise
Swab and Viral Transport Medium Market projected to expand at a CAGR of ~3% from …
Swab and Viral Transport Medium Market: Introduction Transparency Market Research has published a new report titled, ‘Global Swab and Viral Transport Medium Market ’. According to the report, the global swab and viral transport medium market was valued at US$ 0.9 Bn in 2019 and is projected to expand at a CAGR of ~3% from 2020 to 2030. Viral transport medium (VTM) enables safe transfer of viruses, chlamydia, and mycoplasma for
Radiofrequency Ablation Devices Market by Product, Geography and Forecast to 202 …
Transparency Market Research (TMR) has published a new report titled, 'Radiofrequency Ablation Devices for Pain Management Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027'. According to the report, the global radiofrequency ablation devices for pain management market was valued at US$ 543.0 Mn in 2018 and is projected to expand at a CAGR of above 11.0% from 2019 to 2027. Overview Radiofrequency ablation is a minimally invasive surgical

All 5 Releases


More Releases for Small

Small Business Success Platform
OwnersPath.com has developed a small business success platform that helps businesses to locate and pre-qualify for financing, build strong business credit scores, optimize their online marketing, maximize the owners earnings, and increase the business value. The system allows business owners to first run a success scan on their business that returns 150 data points on their business and establishes a base line for the owners as to where their business is
Stimulus for small Business
suisseassociates.com Youtube Channel https://www.youtube.com/watch?v=5WwB1QZEmPk Ever since I was a child I have had a burning desire to help others. In most cases I didn't really think about the price or consequences to me personally. Afterall, that's how I was raised. From my grandparents to my parents, my family sacrificed everything for me. I never missed a meal or didn't have a roof over my head. Moreover, I'm
Small Domestic Appliances 2016
Summary Small domestic appliances appliance market is forecast to be worth £974m in 2016, a decline of 1.1% since 2015, as the post-Brexit fallout increases consumer cautiousness. While inflation will see category values continue to increase it will also hit retailer margins and encourage trading down in products such as irons. While some products, such bladeless fans, are capturing the consumer imagination and boosting growth. Key Findings – In 2016, growth in SDA
Big Data – Small Devices
Are we facing a new way of doing data science? Do we need novel methods for machine learning? On Monday, March 7, leading IT experts will convene at the German Center for Research and Innovation (GCRI) in New York for a discussion on Big Data and resource-restricted systems. NEW YORK (March 3, 2016) – The amount of digitally recorded information in today’s world is growing exponentially. Massive volumes of user-generated information
Small Business Data Protection Needs
The three primary reasons to protect employee generated work data in businesses of all sizes are: to restore data that was lost, to retrieve an earlier version if current version is corrupted, and to recover all important business data if the work place suffers a natural disaster. The solution must perform the job automatically, consistently and do it without interfering with the way employees work. Smaller businesses on the other hand
Small Talk is Huge!
(Lisle IL) The content can be current chitchat; the role small talk plays, however, is far from minor, according to Lillian Bjorseth, a face-to-face business networking authority. “It’s an enormously important conversation starter and often determines if you want to keep talking – hence the opportunity to build a relationship – or make a quick escape,” added the owner of Duoforce Enterprises, Inc. Because the content may seem unimportant (let’s